Meeting Banner
Abstract #4286

Developing CEST-detectable liposomal hydrogel for monitoring local brain tumor treatment

Se Weon Park1,2, Joseph H.C Lai1, Xiongqi Han3, Jianpan Huang1, Peng Xiao1, and Kannie W.Y. Chan1,4,5
1Department of Biomedical Engineering, City University of Hong Kong, Hong Kong, Hong Kong, 2Hong Kong Centre for Cerebro-Cardiovascular Health Engineering (COCHE), Hong Kong, Hong Kong, 3SiBionics, Shenzhen, China, 4Russell H. Morgan Department of Radiology and Radiological Science, The Johns Hopkins University School of Medicine, Baltimore, MD, United States, 5City University of Hong Kong Shenzhen Research Institute, Shenzhen, China


Glioblastoma is a malignant form of brain tumors, which has a high recurrence even with combined treatments. Here, we developed anti-cancer drugs loaded liposomal hydrogels for sustainable drug release to treat brain tumors locally under MRI guidance. These anti-cancer drugs are CEST-detectable. We observed a continuous decrease in tumor size and CEST contrast at 3.5 and -3.5 ppm compared to control group, where drug-free liposomal hydrogel was injected. The therapeutic efficacy of local drug delivery using liposomal hydrogel was evidenced and can be monitored using CEST multiple-contrast approach. This could serve a robust theranostic application for local brain tumor treatment.

This abstract and the presentation materials are available to members only; a login is required.

Join Here